A newly authorized point-of-care diagnostic could cut the wait for a COVID-19 diagnosis from days to hours, the US Food and Drug Administration announced on 21 March.
The Xpert Xpress SARS-CoV-2 test, developed by Danaher Corp. business unit Cepheid, uses samples collected via a nasal swab or nasal wash, and offers results in as little as...